Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

Publication in NPJ Vaccines highlights delivery of DNA vaccine with PharmaJet Needle-free IM System produces robust and ...

The DDL Conference, taking place in Edinburgh, Scotland, attracts over 1,000 global experts annually, including scientists, clinicians, and industry leaders. Belhaven Biopharma will present these ...

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...